Jean-Bernard Lazaro, PhDDana-Farber Cancer Institute Targeting DNA repair genes and the nucleolar proteome to increase cisplatin sensitivity in ovarian cancer Patients with ovarian cancer who are treated with cisplatin often develop resistance to the drug, as cisplatin acts by damaging cellular DNA, which in turn induces apoptosis. Repair of cisplatin-induced DNA damage by a few […]
Read More
Keren Levanon, MD, PhDDana-Farber Cancer Institute The Fallopian Tube as field of origin of ovarian serous carcinoma Research on ovarian carcinogenesis has traditionally focused on the ovarian surface epithelium as the fields of origin. More recently, the secretory cell of the fallopian tube has emerged as an alternate cell-of-origin for ovarian and pelvic serous carcinomas, […]
Read More
Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read More
Benjamin Izar, MD, PhDDana-Farber Cancer Institute Single-cell transcriptome analysis of treatment-resistant ovarian cancer and new strategies for drug discovery Dr. Izar will be studying in fine detail the molecular changes that take place from the time that ovarian cancer cells respond to platinum chemotherapy to when they become resistant. He will employ an innovative genetic […]
Read More
Elizabeth Harmon Stover, MD, PhDDana-Farber Cancer Institute Genomic analysis of plasma cell-free tumor DNA to evaluate clinical mechanisms of drug resistance in ovarian cancer Many ovarian cancers are able to resist drug treatment and therefore recur after months or years, posing a major challenge for clinicians and researchers. Currently research of resistant tumors is limited […]
Read More
Dipanjan Chowdhury, PhDDana-Farber Cancer Institute OC130658: Noncoding RNAs as Prognostic and Predictive Biomarkers in BRCA 1/2-Mutated and Wildtype Epithelial Ovarian Cancer Patients with epithelial ovarian cancer that carry BRCA1 or BRCA2 mutations can successfully be treated with platinum chemotherapy and PARP inhibitors because the BRCA1/2 mutations cause a defect in DNA repair. This allows the […]
Read More
Alan D’Andrea, MDDana-Farber Cancer Institute Novel mechanisms of PARP-inhibitor resistance in BRCA2-deficient ovarian and breast cancer PARP inhibitors are a promising class of drugs for the treatment of ovarian cancers with defects in the BRCA1 or BRCA2 genes. However, drug resistance to PARP inhibitors poses a significant challenge for clinicians. Dr. D’Andrea’s group has recently […]
Read More